Review
doi: 10.1136/dtb.2009.08.0033.
Tocilizumab for rheumatoid arthritis
- PMID: 20040568
- DOI: 10.1136/dtb.2009.08.0033
Item in Clipboard
Review
Tocilizumab for rheumatoid arthritis
Drug Ther Bull.
2010 Jan.
Abstract
Tocilizumab (RoActemra-Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid arthritis.1 Unlike currently available biological agents, the drug targets the pro-inflammatory cytokine interleukin-6 (IL-6). Here, we consider the place of tocilizumab in rheumatoid arthritis and whether it offers any advantages over other biological agents.
Similar articles
-
[New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].Ter Arkh. 2010;82(5):64-71. Ter Arkh. 2010. PMID: 20597275 Review. Russian.
-
Rituximab (Rituxan) for rheumatoid arthritis.Med Lett Drugs Ther. 2006 Apr 24;48(1233):34-5. Med Lett Drugs Ther. 2006. PMID: 16625143 Review. No abstract available.
-
[Guidelines for usage of biological agents for treatment of rheumatoid arthritis].Nihon Rinsho. 2005 Jan;63 Suppl 1:444-7. Nihon Rinsho. 2005. PMID: 15799396 Review. Japanese. No abstract available.
-
Anti-interleukin-6 therapy in rheumatoid arthritis.Bull NYU Hosp Jt Dis. 2010;68(3):211-7. Bull NYU Hosp Jt Dis. 2010. PMID: 20969554 Review.
-
Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S16-20. Bull NYU Hosp Jt Dis. 2007. PMID: 17708740 Review.
Cited by
-
Signaling pathways in rheumatoid arthritis: implications for targeted therapy.Signal Transduct Target Ther. 2023 Feb 17;8(1):68. doi: 10.1038/s41392-023-01331-9. Signal Transduct Target Ther. 2023. PMID: 36797236 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
